BioSante Pharmaceuticals to Present at Upcoming Conferences
Lincolnshire, Illinois (October 2, 2007) – BioSante Pharmaceuticals (AMEX: BPA) today announced that Stephen M. Simes, its President and CEO will present a corporate overview and update at two upcoming conferences. The conferences are:
- The Think Equity Partners Annual Growth Conference today, October 4, 2007 at 9:40 a.m. local time at the Pierre Hotel in New York.
- The Bio Investor Forum on October 10, 2007 at 11:15 a.m. local time at the Palace Hotel in San Francisco.
These conferences each feature companies presenting to a diverse group of investors, portfolio managers and analysts interested in the biotechnology and pharmaceuticals sectors as well as industry representatives.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante’s lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante’s licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD).
Also in development is Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine. Additional information is available online at www.biosantepharma.com.
For more information please contact:
Harris D. McKinney, Inc.